These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23919)

  • 21. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
    [No Abstract]   [Full Text] [Related]  

  • 22. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
    Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H
    Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Schizophrenia and its treatment].
    Fünfgeld EW; Kulhanek F
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1979; 7(3):169-80. PubMed ID: 382761
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
    Mindham RH
    Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):395-400. PubMed ID: 9965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Experience with the use of midantan for treatment and prevention of the neuroleptic syndrome].
    Kamianov IM; Kupisk AG; Katsen IZ
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(8):1218-23. PubMed ID: 4149581
    [No Abstract]   [Full Text] [Related]  

  • 26. A comparative double blind trial of pimozide and fluphenazine in chronic schizophrenia.
    Morris PA; MacKenzie DH; Masheter HC
    Br J Psychiatry; 1970 Dec; 117(541):683-4. PubMed ID: 4923721
    [No Abstract]   [Full Text] [Related]  

  • 27. Dosage and side effect comparisons betweel oral and depot fluphenazine.
    Schooler NR; Levine J
    Psychopharmacol Bull; 1977 Jul; 13(3):29-31. PubMed ID: 329328
    [No Abstract]   [Full Text] [Related]  

  • 28. A controlled study of neuroleptization with fluphenazine hydrochloride injections.
    Escobar JI; Barron A; Kiriakos R
    J Clin Psychopharmacol; 1983 Dec; 3(6):359-62. PubMed ID: 6139394
    [No Abstract]   [Full Text] [Related]  

  • 29. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients.
    Iqbal MJ; Young MA; Charles J; Elgart B; Von Greiff H; Simpson GM
    J Clin Psychiatry; 1978 Apr; 39(4):375-9. PubMed ID: 580285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms.
    Chouinard G; Annable L; Mercier P; Turnier L
    Psychopharmacol Bull; 1987; 23(1):221-6. PubMed ID: 2885889
    [No Abstract]   [Full Text] [Related]  

  • 32. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC; Kennedy NM; Gribbon D
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neuroleptic infusion therapy with high-dosed fluphenazine (author's transl)].
    Fünfgeld EW; Kulhanek F
    Arzneimittelforschung; 1978; 28(9):1489-91. PubMed ID: 383096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long persisting drug-induced parkinsonism--a case report.
    Hirschberg E
    Pharmacopsychiatry; 1987 Nov; 20(6):278. PubMed ID: 3432362
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics.
    Manos N; Lavrentiadis G; Gkiouzepas J
    J Clin Psychiatry; 1986 Mar; 47(3):114-6. PubMed ID: 2869027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug monitoring at an Australia depot phenothiazine clinic.
    Marriott P; Hiep A
    J Clin Psychiatry; 1978 Mar; 39(3):206-12. PubMed ID: 580271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical experience with fluphenazine decanoate in psychoses].
    Náhunek K; Rodová A; Svestka J
    Act Nerv Super (Praha); 1970 Jan; 12(1):47-9. PubMed ID: 5460564
    [No Abstract]   [Full Text] [Related]  

  • 39. Institutional management of chronic schizophrenics with fluphenazine decanoate.
    Neal CD; Imlah NW
    Dis Nerv Syst; 1970 Sep; 31():Suppl:24-7. PubMed ID: 4920310
    [No Abstract]   [Full Text] [Related]  

  • 40. Lisuride in parkinsonism.
    Parkes JD; Schachter M; Marsden CD; Smith B; Wilson A
    Ann Neurol; 1981 Jan; 9(1):48-52. PubMed ID: 7212665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.